DiaMedica Inc.  

(Public, CVE:DMA)   Watch this stock  
Find more results for DMA
+0.010 (1.19%)
Apr 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.83 - 0.85
52 week 0.75 - 1.49
Open 0.83
Vol / Avg. 15,700.00/29,643.00
Mkt cap 50.09M
P/E     -
Div/yield     -
EPS -0.21
Shares 58.93M
Beta 0.41
Inst. own     -
Feb 11, 2014
DiaMedica Inc at Biotechnology Industry Organization CEO & Investor Conference

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -228.59% -194.41%
Return on average equity -343.34% -239.78%
CDP Score - -


Suite 124, One Carlson Parkw
United States - Map
+1-763-7104452 (Phone)
+1-204-4533745 (Fax)

Website links


DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company´┐Żs DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.

Officers and directors

Rick Pauls Chairman of the Board, President, Chief Executive Officer
John Savage Chief Financial Officer
James T. Parsons Vice President - Finance, Corporate Secretary
Mark Robbins Ph.D., J.D. Vice President - Clinical and Regulatory Affairs
Mark Williams Ph.D. Vice President - Research
Edward Rady Senior Consultant - Licensing and Partnering
Michael Giuffre MD Independent Director
Richard D. Pilnik Independent Director
Age: 56
Dawson J. Reimer Independent Director
Age: 42
Thomas G. Wellner Independent Director